Related Experiment Videos
Genetically engineered particulate virus-like structures and their use as vaccine delivery systems
1Department of Biochemistry, University of Oxford, UK.
Intervirology
|January 1, 1996
Summary
Novel baculovirus expression systems create safe and effective bluetongue virus-like particles (VLPs). These noninfectious VLPs are highly immunogenic in sheep, offering a promising alternative to traditional vaccines.
Area of Science:
- Virology
- Vaccinology
- Biotechnology
Background:
- Orbivirus genus viruses, like bluetongue virus (BTV), are complex, nonenveloped viruses with double-stranded RNA genomes.
- BTV causes significant disease in livestock, necessitating effective vaccine development.
Purpose of the Study:
- To develop highly protective virus-like particles (VLPs) for bluetongue disease.
- To utilize novel baculovirus multigene expression systems for VLP production.
Main Methods:
- Coexpression of multiple BTV genes (three to five) using single recombinant baculovirus vectors.
- Characterization of resultant particulate structures for resemblance to BTV particles.
- Preliminary clinical trials in sheep to assess safety and efficacy.
Main Results:
- Structurally and immunologically indistinguishable BTV virus-like and subvirus-like particles were produced.
- VLPs demonstrated noninfectious nature, lacking viral RNA/DNA for replication.
- Sheep trials confirmed VLPs are safe, highly immunogenic, and elicit humoral, cell-mediated, and mucosal immunity.
Conclusions:
- Baculovirus-expressed VLPs represent a safe and effective vaccine platform against bluetongue virus.
- The expression system is versatile, applicable to producing vaccines, insecticides, and diagnostic reagents.